CLINICAL IMMUNOLOGY
Significant reduction of peripheral blood interleukin-35 and CD4+EBI3+ T cells, which are negatively correlated with an increase in the plasma IL-17 and cTnI level, in viral myocarditis patients
Submission date: 2016-01-01
Acceptance date: 2016-01-29
Publication date: 2017-02-16
Cent Eur J Immunol 2017;42(1):91-96
KEYWORDS
ABSTRACT
Introduction: Viral myocarditis (VMC) has become an increasingly common heart disease that endangers human health. In the present study, the plasma interleukin-35 (IL-35) level and the percentage of CD4+EBI3+ T cells in VMC patients were detected to investigate the significance of changes in these parameters in the plasma of VMC patients and their association with the disease.
Material and methods: ELISA was performed to detect the plasma IL-35 level and the percentage of peripheral blood CD4+EBI3+ T cells in 40 VMC patients and in 20 healthy individuals. Moreover, the plasma IL-17 levels in the VMC patients and in the healthy individuals were detected using an ELISA, and the cardiac Troponin-I (cTnI) levels were detected using a chemiluminescent microparticle immunoassay to compare the differences in the groups.
Results: Plasma IL-35 level and the percentage of CD4+EBI3+ T cells in acute phase VMC patients was lower than that in the healthy control group and the convalescent phase VMC patients. Additionally, the plasma IL-35 level in the VMC patients exhibited a negative correlation with the levels of cTnI and IL-17. The percentage of CD4+EBI3+ T cells also showed a negative correlation with the levels of cTnI and IL-17.
Conclusions: The plasma IL-35 level and the percentage of CD4+EBI3+ T cells in VMC patients was reduced, and the amount of the decrease was associated with the severity of the disease. These results suggest that IL-35 and CD4+EBI3+ T might play important roles in the progression of VMC and could be used as indictors of the disease.
Material and methods: ELISA was performed to detect the plasma IL-35 level and the percentage of peripheral blood CD4+EBI3+ T cells in 40 VMC patients and in 20 healthy individuals. Moreover, the plasma IL-17 levels in the VMC patients and in the healthy individuals were detected using an ELISA, and the cardiac Troponin-I (cTnI) levels were detected using a chemiluminescent microparticle immunoassay to compare the differences in the groups.
Results: Plasma IL-35 level and the percentage of CD4+EBI3+ T cells in acute phase VMC patients was lower than that in the healthy control group and the convalescent phase VMC patients. Additionally, the plasma IL-35 level in the VMC patients exhibited a negative correlation with the levels of cTnI and IL-17. The percentage of CD4+EBI3+ T cells also showed a negative correlation with the levels of cTnI and IL-17.
Conclusions: The plasma IL-35 level and the percentage of CD4+EBI3+ T cells in VMC patients was reduced, and the amount of the decrease was associated with the severity of the disease. These results suggest that IL-35 and CD4+EBI3+ T might play important roles in the progression of VMC and could be used as indictors of the disease.
REFERENCES (22)
1.
Kindermann I, Barth C, Mahfoud F, et al. (2012): Update on myocarditis. J Am Coll Cardiol 59: 779-792.
2.
Ohshima M, Yamaharak, Ishikanes, et al. (2012): Systemic transplantation of allogenic fetal membrane-derived mesenchymal stem cells suppresses Th1 and Th17 T cell responses in experimental autoimmune myocarditis. J Mol Cell Cardiol 53: 420-428.
3.
Devergne O, Birkenbach M, Kieff E (1997): Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA 94: 12041-12046.
4.
Niedbala W, Wei XQ, Cai B, et a1. (2007): IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 37: 3021-3029.
5.
Collison LW, Workman CJ, Kuo TT, et a1. (2007): The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569.
6.
Murdaca G, Colombo BM, Puppo F (2011): The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases.Internal and Emergency Medicine 6: 487-495.
7.
Crispín JC, Oukka M, Bayliss G, et al. (2008): Expanded double negative t cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 181: 8761-8766.
8.
Dańczak-Pazdrowska A, Kowalczyk M, Szramka-Pawlak B, et al. (2012): Interleukin-17A and interleukin-23 in morphea.Arch Med Sci; 8: 1089-95.
9.
Li S, Li Y, Qu X, et al. (2014): Detection and significance of TregFoxP3(+) and Th17 cells in peripheral blood of non-small cell lung cancer patients.Arch Med Sci; 10: 232-239.
10.
Xie Y, Chen R, Zhang X, et al. (2011): The role of Th17 cells and regulatory T cells in Coxsackievirus B3-induced myocarditis. Virology 1421: 78-84.
11.
Banchereau J, Pascual V, OGarra A (2012): From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 13: 925-931.
12.
Matsui Y, Inobe M, Okamoto H, et al. (2012): Blockade of T cell costimulatory signals using adenovirus vectors prevents both the induction and the progression of experimental autoimmune myocarditis. J Mol Cell Cardiol 34: 279-295.
13.
Whitehead GS, Wilson RH, Nakano K, et a1. (2012): IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease. J Allergy Clin Immunol 129: 207-215.
14.
Devergne O, Hummel M, Koeppen H, et a1. (1996): A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol 70: 1143-1145.
15.
Niedobitek G, Päzolt D, Teichmann M, et a1. (2002): Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 198: 310-316.
16.
Yang J, Yang M, Htut TM, et a1. (2008): Epstein-Barr virusinduced gene 3 negatively regulates IL-17, IL-22 and RORt. Eur J Immunol 38: 1204-1214.
17.
Pope RM, Shahrara S (2013): Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol 9: 252-256.
18.
Han Ouyang, Yong-bing Shi, Zhi-chun Liu, et a1. (2014): Decreased Interleukin 35 and CD4+EBI3+ T cells in Patients With Active Systemic Lupus Erythematosus. Am J Med Sci 348: 156-161.
19.
Yuan J, Yu M, Lin QW, et al. (2010): Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis. Int Immunopharmacol 10: 272-6.
20.
Ye S, Wu J, Zhou L, et al. (2013): Interleukin-35: the future of hyperimmune- related diseases. J Interferon Cytokine Res 33: 285-291.
21.
Neurath MF (2008): IL-12 family members in experimental colitis. Mucosal Immunol 1 (Suppl 1) 28-30.
22.
Hu Y, Dong C, Yue Y, et al. (2014): In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells. Arch Virol 159: 2411-2419.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
